Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Science

26 Sep 2024

Can You Reverse Aging? Interview with Maxwell Biosciences’ CEO Joshua “Scotch” McClure

Can aging be stopped or even reversed? Micodose sat down with Maxwell Biosciences' CEO to discuss better health and lifespans....

By Jason Najum

Breaking News

5 Jun 2024

FDA Advisory Committee Rejects Lykos’ MDMA Therapy For PTSD

An FDA advisory panel has rejected the approval of MDMA as a treatment for post-traumatic stress disorder (PTSD). The FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) met to review Lykos Therapeutics’...

By Jason Najum

Industry

28 Dec 2023

The Top Psychedelic Stories of 2023

As we close out the year, let’s take a look back at some of the more important milestones in the psychedelic medicine space. From legalization to clinical trials, the psychedelic...

By Jason Najum

Culture

22 Dec 2023

Santa’s Trippy Origins: Exploring the Psychedelic Roots of Christmas

We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of Christmas history....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

8 Dec 2023

Terran Biosciences Granted Four Patents for New Forms of Psychedelics

Terran’s new patents cover new psilocybin forms, orally active DMT, and 5-MeO-DMT, and novel forms of ibogaine derivative tabernanthalog....

By Jason Najum

Breaking News

31 Oct 2023

Cybin Announces Positive Phase 2 Data for Phase 2 Depression Trial

This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint....

By Jason Najum

Law & Politics

20 Oct 2023

Eureka! California City Approves Psychedelic Decriminalization

Eureka, California has become the latest city to decriminalize psychedelic medicines....

By Jason Najum

Culture

19 Oct 2023

Harvard Launches New Study of Psychedelics in Society and Culture

Backed by a $16 million donation, Harvard is creating a new Study of Psychedelics in Society and Culture....

By Jason Najum

Finance

18 Oct 2023

Spravato Sales Lead J&J Third Quarter Results

Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth....

By Jason Najum

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.